The US FDA has approved a pentavalent meningococcal vaccine for individuals aged 10-25 years, targeting serogroups A, B, C, W, and Y of Neisseria meningitidis. Clinical evidence In clinical trials, the pentavalent vaccine demonstrated an 84% seroresponse against meningococcal serogroup B strains and over 95% against serogroups A, C, W, and Y. Dosage and administration Two doses, six months apart Contraindications Severe allergic reaction (e.g., anaphylaxis) to any component of this vaccine, or any other diphtheria toxoid-containing vaccine Warnings and precautions Syncope (fainting) Adverse reactions Fatigue, headache, myalgia, nausea, erythema, and swelling Did you find this FDA Alert interesting?
Source : FDA ##Disclaimer## The content provided on Docplexus is intended for educational purposes only. While we strive to ensure its accuracy, we make no warranties, explicit or implied,…
